A surge of attention-grabbing information within the lung most cancers house got here from the 2024 American Society of Scientific Oncology (ASCO) Annual Assembly. In accordance with Aakash Desai, MD, MPH, some consultants have even referred to the assembly ASCO Lung as a substitute of ASCO 2024.
“We’re excited to see lots of progress being made in lung most cancers, it being one of many cancers with the very best mortality,” Desai, thoracic and part 1 medical oncologist and assistant professor on the O’Neal Most cancers Middle on the College of Alabama, Birmingham, instructed Focused OncologyTM, in an interview.
One theme of curiosity from the assembly was the usage of focused therapies, notably for sufferers with oncogene-driven non–small cell lung most cancers (NSCLC), and information from trials like PACIFIC (NCT02125461), LAURA (NCT03521154), CROWN (NCT03052608), and extra have paved the way in which to new and potential therapeutic for lung most cancers remedy.1,2,3
Desai additionally famous the promising outcomes from the ADRIATIC research (NCT03703297) in limited-stage small cell lung most cancers (SCLC) the place, at a median follow-up of 37.2 months (vary, 0.1-60.9), the median total survival noticed amongst sufferers handled with durvalumab (Imfinzi; n = 264) was 55.9 months (95% CI, 37.3-not evaluable) in contrast with 33.4 months (95% CI, 25.5-39.9) for these given placebo (n = 266), translating to a 27% discount within the threat of dying (HR, 0.73; 95% CI, 0.57-0.93; P = .0104).4
Within the interview, Desai mentioned important lung most cancers remedy developments that had been highlighted at ASCO 2024, notably in focused therapies for NSCLC and new remedy methods for limited-stage SCLC.
Focused Oncology: What had been a few of the total themes or areas of biggest progress mirrored within the analysis offered at ASCO 2024?
Desai: At ASCO this 12 months, we noticed lots of attention-grabbing abstracts and shows round lung most cancers. In our oncology neighborhood, there was a dialogue whether or not this was ASCO Lung as a substitute of ASCO 2024. We’re excited to see lots of progress being made in lung most cancers, it being one of many cancers with the very best mortality. Amongst these, the theme that emerged was focused remedy, particularly for the oncogene-driven non–small cell lung most cancers. We additionally had our first kind of advance in small cell lung most cancers, particularly for the restricted stage, in a few years, a few a long time, truly. [I am] excited to see all of the progress and a few of these being already integrated into scientific observe.
Lungs © Mopic – inventory.adobe.com
Are you able to spotlight a number of of these attention-grabbing lung abstracts encountered?
Two of them truly made the plenary, so I am going to speak about these first. The primary was inside the EGFR house for [patients with] unresectable, stage III non–small cell lung most cancers who endure definitive chemoradiotherapy. Pre-ASCO, we didn’t have lots of information on what to do for these sufferers who’ve an EGFR mutation and find yourself being identified with stage III unresectable non–small cell lung most cancers. The standard strategy was based mostly on the PACIFIC research [NCT02125461] the place you give chemoradiation adopted by durvalumab as a consolidation remedy.
There was some concern that durvalumab is probably not an efficacious remedy technique particularly for the oncogene-driven subset like EGFR, so the LAURA research was a part 3 trial that examined osimertinib [Tagrisso] after definitive chemoradiotherapy in sufferers with unresectable, stage III, EGFR-mutated non–small cell lung most cancers. Basically, the research design randomized sufferers to osimertinib 80 mg per day vs placebo following definitive chemoradiation. What we discovered was the median [progression-free survival (PFS)]with osimertinib was 39.1 months in contrast [with] 5.6 months with placebo, an enormous profit when it comes to median progression-free survival. The general survival outcomes had been offered, however they weren’t mature on the time. I feel that is sufficient sturdy proof for me to include this into my scientific observe, when it comes to the sufferers that I see with EGFR-mutated non–small cell lung most cancers and stage III.
What ought to a neighborhood oncologist find out about this analysis?
A neighborhood oncologist ought to perceive the significance of testing for these oncogenes in non–small cell lung most cancers tumors, even in stage III. It has been widespread observe in stage IV for a number of years now, and we’re more and more seeing with this research and different research within the early-stage setting for resected non–small cell lung most cancers that testing for oncogene drivers is changing into more and more necessary as a result of we don’t need to miss a possibility if we are able to put a affected person on a tablet to deal with that lung most cancers relatively than have them are available in for infusions each 3 weeks. Additionally, the [adverse] impact profile is sort of totally different. It does have its personal set of [adverse] results, however once more, nowhere near being as poisonous or as troublesome to tolerate as chemotherapy is. I feel it will be important for us to guarantee that we’re testing all our sufferers for these oncogene drivers.
What had been another updates within the focused remedy house that you may spotlight?
There was a 5-year replace from the CROWN research for the ALK-positive non–small cell lung most cancers, which in contrast lorlatinib [Lorbrena] with crizotinib [Xalkori]. We noticed once more, the median progression-free survival with lorlatinib was not reached in contrast with 9.1 months with crizotinib. Once more, we noticed that at 5 years, 60% of sufferers had been surviving with lorlatinib vs 8% with crizotinib. So once more, an enormous distinction. I feel that is a few of the finest information that we now have on this ALK-positive non–small cell lung most cancers house. Once more, it form of solidifies the truth that first-line lorlatinib continues to reveal sustained systemic, in addition to [central nervous system (CNS)] efficacy with no new security indicators. This was extra of a practice-conforming remedy technique trial. The replace confirms what we predict ought to be the usual of care within the first line with lorlatinib.
There have been another attention-grabbing research as nicely. Particularly, the PALOMA-3 research [NCT01942135] which launched a special formulation of a drug that we generally use in observe referred to as amivantamab-vmjw [Rybrevant] for EGFR-mutated non–small cell lung most cancers. They in contrast subcutaneous vs intravenous [IV] amivantamab on this specific research. Once more, it was a part 3 research taking a look at domestically superior or metastatic non–small cell lung most cancers with the widespread EGFR mutations and randomized sufferers with subcutaneous amivantamab plus lazertinib [Leclaza] vs intravenous amivantamab plus lazertinib. They mentioned actually good outcomes from a pharmacokinetic standpoint, space underneath the curve and such, principally exhibiting that subcutaneous is nearly as good as IV when it comes to the pharmacokinetics of the drug. Additionally, a few of the outcomes that they offered when it comes to median progression-free survival had been comparable, if not higher with the subcutaneous.
We noticed that the adversarial occasions with subcutaneous had been a lot much less when it comes to the infusion-related adversarial occasions, in addition to every other grade 3 adversarial occasions that we noticed. Once more, encouraging, and I feel that is going to be observe altering. Intravenous has lots of logistical challenges when it comes to clinic infusion instances, in addition to time toxicity for sufferers, spending a number of hours of the day within the infusion clinic vs having a subcutaneous choice, which goes to be a lot quicker when it comes to time. So, a superb advance for our sufferers.
Are you able to additional talk about the ADRIATIC research in SCLC?
I feel this has modified and can change scientific observe as soon as it’s accredited. The ADRIATIC research studied durvalumab as consolidation remedy for sufferers with limited-stage small cell lung most cancers. Sufferers with limited-stage small cell lung most cancers presently get chemoradiation with none consolidative remedy. This has been kind of the usual of take care of a few a long time. With this specific research, they did take a look at total survival as a twin major finish level, but additionally PFS. We did see that the median PFS was improved with durvalumab at 16.6 vs 9.2 months. When it comes to the [overall survival], we additionally noticed median total survival profit with durvalumab at 55 months vs 33 with placebo. I feel this is a crucial advance, particularly for small cell lung most cancers, which is a really troublesome to deal with illness and an aggressive illness. For these sufferers with limited-stage SCLC, the choice of incorporating immunotherapy and the outcomes and efficacy that we see is thrilling, and I undoubtedly will use it within the clinic as soon as it’s accredited.
What are a few of the subsequent steps for these promising research that you simply noticed?
Now we have good proof now based mostly on trials. I feel we have to see how these carry out in the actual world and the way we incorporate them into the actual world. I feel the advantages that we’re seeing on the trials does make sense for us to be readily implementing them within the clinics, however we all know from different research and former analysis that real-world practices might differ, so we have to guarantee that these practices conform extra to the rules and the proof that we now have.
What unmet wants nonetheless exist on this house?
I feel the unmet want, particularly for the non-oncogene-driven superior non–small cell lung most cancers, within the second-line house continues to be an unmet want. We had been excited for the presentation on 1 of the antibody-drug conjugates, sacituzumab govitecan-hziy [Trodelvy], which they in contrast with docetaxel within the EVOKE-01 research [NCT05089734], which was a part 3 research. Sadly, that research didn’t present any superiority when it comes to total survival with antibody-drug conjugates in contrast with docetaxel remedy that’s presently customary of care and utilized in clinics. We had been hoping that this might be a superb advance for our sufferers and that we might have an alternative choice to supply, particularly as a result of the sufferers who’ve tumors that are refractory or relapsed after immunotherapy and chemotherapy are usually troublesome to deal with. Sadly, I feel this nonetheless stays an unmet want on this house the place we don’t readily have any choice out there apart from the docetaxel that we now have been utilizing for many years.
Are there any upcoming or ongoing scientific trials investigating new therapies that you simply discover attention-grabbing?
There are a number of when it comes to newer antibody-drug conjugates, in addition to bispecific antibodies. As I discussed, the sacituzumab govitecan TROP2 antibody-drug conjugate trials didn’t pan out, however we now have some information from datopotamab deruxtecan [DS-1062a; Dato-DXd], which is a special antibody-drug conjugate utilizing the identical tumor related antigen, which does have some constructive sign. I feel it stays to be seen how that is learn by the FDA, and whether or not that is accredited or not. Regardless, there’s lots of pleasure within the area for these antibody-based therapies.
There’s one other bispecific antibody ivonescimab [SMT112] and a few information offered at ASCO [that was] performed in China and was encouraging within the EGFR post-osimertinib settings. Once more, as these research change into world and we get extra information from these research, I’m excited for the potential of those antibody-based therapies to alter and enhance outcomes for our sufferers with non–small cell lung most cancers.
